Guillaume Canaud

Guillaume Canaud

ESDR 2022 Clinical Saturday
Title: Targeted therapy in patients with PIK3CA related overgrowth spectrum
Date: Saturday 01 October 2022

Time: 10.00-11.30

Guillaume Canaud is a MD, PhD working at Necker Hospital (Paris). He did his medical school in Montpellier and moved to Paris in 2002 to perform his Residency in Nephrology (2002 to 2007). He became Senior Resident in the Renal Division of Necker (Prof. Legendre) from 2007 to 2012. Concurrently, he spent four years from to 2008 to 2012 in the laboratory of Dr. Fabiola Terzi (INSERM U1151, Necker Hospital) to achieve his PhD degree in molecular and cellular biology. Then, he joined the Joseph Bonventre’s Laboratory (Harvard Medical School, Boston, USA) from 2012 to 2014 to achieve a postdoc. He came back to Christophe Legendre’s team with a Faculty position (Associate Professor) and built his own group of research dedicated to translational medicine. He obtained an European Research Council starting grant (2015) for his kidney research project, an ERC Proof of Concept Grant for his translational research (2016) and an ERC Consolidator (2020) dedicated to the understanding of PIK3CA related disorders. Guillaume is now full professor at the Université de Paris and is working specifically on rare disorders involving the PIK3CA/AKT/mTOR pathway.

Very recently, Guillaume and his group, identified and reported in Nature a very promising therapeutic for patients with a rare genetic disorder called PIK3CA-Related Overgrowth Syndrome.

He published as a first or last author in top leading medical and scientific journals such as Nature, The New England Journal of Medicine, Nature Medicine, Science Translational Medicine or Proceedings of the National Academy of Sciences USA. He received several awards including the 2018 Prize Jean Lecocq of the French Academy of Sciences, the 2019 Prize Eloi Collery of the French Academy of Medicine, the 2019 Ville de Paris Jean Hamburger Prize and the 2021 Unsolicited International Triennial Gagna A. & Ch. Van Heck Prize for Incurable Diseases.

More information on the website: